J. Kazakin

发表

Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)

L. Biesecker, B. Schwartz, Paula Doherty, 2020, Cold Spring Harbor molecular case studies.

First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma

J. Crown, C. Leoni, G. Zampino, 2019, American journal of medical genetics. Part A.

Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC)

B. Schwartz, G. Abbadessa, H. Zahir, 2012 .

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, L. Camacho, 2010 .

Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).

V. Mazzaferro, S. Braun, K. Papadopoulos, 2019, Journal of Clinical Oncology.

ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.

V. Mazzaferro, K. Papadopoulos, L. Rimassa, 2017 .

Prospective Phase II Trial of PFL-Induction Chemotherapy Followed by Definitive Local Treatment for Advanced Squamous Cell Carcinoma of the Head and Neck: 10-Year Follow-up

S. Adak, R. Tishler, P. Devlin, 2004, American journal of clinical oncology.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

V. Mazzaferro, F. D. De Braud, K. Papadopoulos, 2018, British Journal of Cancer.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

A. Tolcher, K. Papadopoulos, D. Rasco, 2017, British Journal of Cancer.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

V. Mazzaferro, K. Papadopoulos, L. Rimassa, 2018, British Journal of Cancer.

Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.

A. Tolcher, P. LoRusso, K. Papadopoulos, 2015 .

An Internet-ready database for prospective randomized clinical trials of high-dose-rate brachytherapy for adenocarcinoma of the prostate.

T. Mate, G. Gustafson, S. Nag, 2002, International journal of radiation oncology, biology, physics.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors.

J. Bendell, L. Camacho, G. Abbadessa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetric consequences of manual pullback procedure for coronary artery radiotherapy with 90Sr/90Y beta-source.

R. Cormack, L. Chin, P. Devlin, 2004, Brachytherapy.